Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Sanofi : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi Therapeutic

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/20/2017 | 02:57pm CEST
   By Sonia Amaral Rohter 
 

Sanofi SA (>> Sanofi) and Alnylam Pharmaceuticals Inc. (>> Alnylam Pharmaceuticals, Inc.) reported Wednesday that Patisiran met all primary and secondary endpoints in a Phase III trial of its use against a rare, inherited disorder.

The trial looked at the use of Patisiran in patients with hereditary transthyretin-mediated amyloidosis, a progressively debilitating disease in which a gene mutation causes the production of a type of abnormal protein that accumulates in body organs and tissues, damaging them. Patisiran is designed to target and silence the mechanism that leads to production of this protein.

Patisiran is part of a class of medicines called RNA interference, or RNAi, therapeutics that aim to inhibit the expression of certain genes in order to treat or prevent disease.

Alnylam Chief Executive John Maraganore said: "We are very proud to report the first-ever positive Phase III results for an RNAi therapeutic, marking the potential arrival of an entirely new class of medicines."

Alnylam said it would file a new drug application with the U.S. Food and Drug Administration in late 2017. Should the company receive regulatory approval, Alnylam will commercialize Patisiran in the U.S., Canada and Western Europe, while Sanofi Genzyme will commercialize the product in the rest of the world.

The full results of the trial will be presented on November 2.

Write to Sonia Amaral Rohter at sonia.amaralrohter@dowjones.com

Stocks mentioned in the article : Sanofi, Alnylam Pharmaceuticals, Inc.
Stocks mentioned in the article
ChangeLast1st jan.
ALNYLAM PHARMACEUTICALS, INC. 0.43% 93.75 Delayed Quote.-26.21%
SANOFI 0.00% 74.89 Real-time Quote.4.25%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
09/18SANOFI : unveils eczema drug data, as regulators mull label expansion
AQ
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/17SANOFI : Disclosure of trading in own shares
GL
09/17SANOFI : Positive Phase 3 results presented for Dupixent (dupilumab)
AQ
09/15SANOFI : Positive Phase 3 results presented for Dupixent® (dupilumab)
AQ
09/15SANOFI : Positive Phase 3 results presented for Dupixent® (dupilumab)
GL
09/14REGENERON PHARMACEUTICALS : FDA to Review Supplemental Biologics License Applica..
AQ
09/14SANOFI : creating China/emerging markets and primary care units
AQ
09/14SANOFI : swaps top execs with Bayer, triggering a reorganization that puts China..
AQ
09/13FINDINGS FROM SANOFI PROVIDE NEW INS : Coadministration of Selective Glucagon an..
AQ
More news
News from SeekingAlpha
09/15Regeneron and Sanofi's Dupixent shows treatment benefit in adolescents with a.. 
09/15STOCKS TO WATCH : Oracle Looks To Lift Tech Sector 
09/14Sanofi (SNY) Presents at Bank of America Merrill Lynch Global Healthcare Conf.. 
09/13Sanofi to refocus two global business units 
09/1236 'Safer' Dividend Healthcare WallStars For September 
STOCK PICK
At a crossroads
Financials (€)
Sales 2018 35 107 M
EBIT 2018 8 381 M
Net income 2018 5 005 M
Debt 2018 16 227 M
Yield 2018 4,10%
P/E ratio 2018 18,17
P/E ratio 2019 16,90
EV / Sales 2018 3,13x
EV / Sales 2019 3,02x
Capitalization 93 747 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 80,2 €
Spread / Average Target 7,1%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI4.25%109 911
JOHNSON & JOHNSON0.59%375 479
PFIZER18.75%252 129
NOVARTIS-1.14%215 800
ROCHE HOLDING LTD.-4.00%212 015
MERCK AND COMPANY25.15%187 284